Ratings for DexCom DXCM were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 4 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 6 | 4 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for DexCom, revealing an average target of $107.6, a high estimate of $145.00, and a low estimate of $75.00. Experiencing a 25.83% decline, the current average is now lower than the previous average price target of $145.07.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive DexCom is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matt Miksic | Barclays | Lowers | Equal-Weight | $113.00 | $138.00 |
| Marie Thibault | BTIG | Lowers | Buy | $120.00 | $156.00 |
| Patrick Wood | Morgan Stanley | Lowers | Equal-Weight | $75.00 | $120.00 |
| Steven Lichtman | Oppenheimer | Lowers | Outperform | $115.00 | $150.00 |
| Danielle Antalffy | UBS | Lowers | Buy | $95.00 | $163.00 |
| Mathew Blackman | Stifel | Lowers | Buy | $90.00 | $132.00 |
| Matt O'Brien | Piper Sandler | Lowers | Overweight | $90.00 | $150.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $145.00 | $165.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $80.00 | $145.00 |
| William Plovanic | Canaccord Genuity | Lowers | Buy | $89.00 | $145.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $75.00 | $145.00 |
| William Plovanic | Canaccord Genuity | Maintains | Buy | $145.00 | $145.00 |
| Patrick Wood | Morgan Stanley | Lowers | Equal-Weight | $120.00 | $132.00 |
| Mathew Blackman | Stifel | Lowers | Buy | $132.00 | $145.00 |
| Issie Kirby | Redburn Atlantic | Announces | Neutral | $130.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of DexCom compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of DexCom's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into DexCom's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on DexCom analyst ratings.
Unveiling the Story Behind DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
DexCom's Economic Impact: An Analysis
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: DexCom displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 15.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: DexCom's net margin excels beyond industry benchmarks, reaching 14.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): DexCom's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): DexCom's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 1.07, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Basics of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
